144P - Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the rad...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Surgical Oncology
Non-Small Cell Lung Cancer
Radiation Oncology
Presenter Sara Marin
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors S. Marin1, J. Garde2, C. Salvador Coloma3, O. Juan3, L. Arribas4, J. García Sánchez1, C. Escoin Pérez3, J. Hidalgo Coloma1, R.A. Albino Pérez1, A. Llombar Cussac1
  • 1Medical Oncology, Hospital Arnau de Vilanova, 46015 - Valencia/ES
  • 2Medical Oncology, Hospital Arnau de Vilanova, Valencia/ES
  • 3Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 4Radiotherapeutic Oncology, Fundación Instituto Valenciano de Oncología, Valencia/ES



Non-small-cell lung cancer oligometastatic at diagnosis represents a therapeutic challenge. Nowadays we have limited evidence about the radical treatment benefit for the primary tumor and the metastases.


Retrospective study of patients with NSCLC unresectable and oligometastatic (3 or less lesions, in a unique location), radical treated the primary tumor and the metastases. We have done a systematic review of the clinical histories from NSCLC advanced patients diagnosed between October 2011 and November 2015. The aim of our study is to analyze the safety and efficacy of this treatment strategy in terms of response rate, progression free survival (PFS) and overall survival (OS).


34 patients met inclusion criteria. Median age 58 years, male (78.3%) and ECOG (0–1) 95.7%. Histology: adenocarcinoma (64.7%), squamous carcinoma (23.5%), sarcomatoid (5.8%) and other histology (5.8%). All patients have unresectable mediastinal lymph nodes. Oligometastase location brain metastases (64.7%), lung metastases (17.6%), bone metastases (8.8%), other location (5.8%). Chemotherapy: CDDP–pemetrexed (41.1%), CDDP–vinorelbine (35.29%), carboplatin–paclitaxel (8.8%), CDDP–gemcitabine (5.8%), CDDP–docetaxel (5.8%). Sequential thoracic radiotherapy (43.5%) and concomitant radiotherapy (52.2%). Metastase treatment: Radiosurgery (58.8%), external radiotherapy (23.5%), surgery (11.7%), radiofrequency (2.9%), none (2.9%). Toxicity G3 (29.4%). Response rate (68.9%), PFS 12 months (95% CI: 8.2–13.7), OS 19 months (CI: 15.6–21.3).


The radical treatment in oligometastatic unresectable NSCLC patients is a safe therapeutic strategy. Despite the limited data of prospective and randomized studies, it could be contemplated as an effective therapeutic alternative in selected patients.

Clinical trial identification

Legal entity responsible for the study

Hospital Arnau de Vilanova




All authors have declared no conflicts of interest.